A multifunctional anti-O-Antigen human monoclonal antibody protects against <i>Shigella sonnei</i> infection in vivo

M Matteo Ridelfi G Giacomo Vezzani (GSK Vaccines Institute for Global Health) E Emanuele Roscioli G Giampiero Batani E Elena Boero (GSK Vaccines Institute for Global Health) F Francesco Nannini (Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences) E Eleonora Marini (Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences) U Ushasi Bhaumik (Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine) G Girmay Desalegn (Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine) O Ornella Serpino (Dipartimento di Scienze Chimiche, Università degli Studi di Napoli Federico II) A Antonio Molinaro (Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg and Sahlgrenska University Hospital) I Ida Paciello C Chiara Mugnaini C Concetta De Santi G Giuseppe Maccari A Antonella De Rosa (Fondazione Toscana Life Sciences) S Silvia Valensin (Fondazione Toscana Life Sciences) A Assia Duatti (GSK Vaccines Institute for Global Health) R Roberta Di Benedetto (GSK Vaccines Institute for Global Health) M Maria Michelina Raso (GSK Vaccines Institute for Global Health) R Renzo Alfini (GSK Vaccines Institute for Global Health) C Chiara Sammicheli (GlaxoSmithKline) S Simona Tavarini (GlaxoSmithKline) C Christina Quigley (Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center) A Audino Podda (GSK Vaccines Institute for Global Health) A Anna Kabanova E Emanuele Andreano (Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences) D Dario Cardamone G Gianmarco Gasperini (GSK Vaccines Institute for Global Health) F Francesca Necchi (GSK Vaccines Institute for Global Health) M Mariagrazia Pizza (GSK Vaccines Institute for Global Health) L Laura B. Martin (GSK Vaccines Institute for Global Health) R Robert W. Frenck (Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center) A Alexandre Grassart (Institut Pasteur de Lille) A Alba Silipo (Dipartimento di Scienze Chimiche, Università degli Studi di Napoli Federico II) M Marcela F. Pasetti (Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine) F Francesco Berlanda Scorza (GSK Vaccines Institute for Global Health) C Carlo Giannelli (GSK Vaccines Institute for Global Health) O Omar Rossi (GSK Vaccines Institute for Global Health) F Francesca Micoli (GSK Vaccines Institute for Global Health) C Claudia Sala R Rino Rappuoli

Abstract

Shigellosis is a global public health challenge that mostly affects low- and middle-income countries and causes considerable morbidity and mortality among children under 5 y of age. Multi- and extensively drug-resistant Shigella sonnei strains associated with recent outbreaks in high-income countries exacerbate the problem and have prompted the World Health Organization to include Shigella spp. among the high-risk pathogens for which novel prophylactic and therapeutic tools are urgently needed. Among the most promising and cutting-edge solutions, monoclonal antibodies are gaining considerable attention in the infectious diseases field. Here, we report the discovery of human monoclonal antibodies against S. sonnei , a species whose prevalence is constantly increasing worldwide and is associated with frequent drug-resistant infections. We isolated antibodies generated in response to an experimental S. sonnei vaccine followed by a controlled human infection and screened them by using a panel of high-throughput assays. We identified a molecule which exhibited potent bactericidal activity in vitro, inhibition of invasion of epithelial cells and conferred full protection from S. sonnei infection in vivo. Overall, our study provides a candidate antibody that can rapidly progress to industrial development for application as a prophylactic, therapeutic, and diagnostic tool against shigellosis.

Article Details

Volume / Issue Vol. 122, Issue 30
Published July 29, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (42)

M

Matteo Ridelfi

G

Giacomo Vezzani

GSK Vaccines Institute for Global Health

E

Emanuele Roscioli

G

Giampiero Batani

E

Elena Boero

GSK Vaccines Institute for Global Health

F

Francesco Nannini

Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences

E

Eleonora Marini

Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences

U

Ushasi Bhaumik

Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine

G

Girmay Desalegn

Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine

O

Ornella Serpino

Dipartimento di Scienze Chimiche, Università degli Studi di Napoli Federico II

A

Antonio Molinaro

Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg and Sahlgrenska University Hospital

I

Ida Paciello

C

Chiara Mugnaini

C

Concetta De Santi

G

Giuseppe Maccari

A

Antonella De Rosa

Fondazione Toscana Life Sciences

S

Silvia Valensin

Fondazione Toscana Life Sciences

A

Assia Duatti

GSK Vaccines Institute for Global Health

R

Roberta Di Benedetto

GSK Vaccines Institute for Global Health

M

Maria Michelina Raso

GSK Vaccines Institute for Global Health

R

Renzo Alfini

GSK Vaccines Institute for Global Health

C

Chiara Sammicheli

GlaxoSmithKline

S

Simona Tavarini

GlaxoSmithKline

C

Christina Quigley

Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center

A

Audino Podda

GSK Vaccines Institute for Global Health

A

Anna Kabanova

E

Emanuele Andreano

Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences

D

Dario Cardamone

G

Gianmarco Gasperini

GSK Vaccines Institute for Global Health

F

Francesca Necchi

GSK Vaccines Institute for Global Health

M

Mariagrazia Pizza

GSK Vaccines Institute for Global Health

L

Laura B. Martin

GSK Vaccines Institute for Global Health

R

Robert W. Frenck

Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center

A

Alexandre Grassart

Institut Pasteur de Lille

A

Alba Silipo

Dipartimento di Scienze Chimiche, Università degli Studi di Napoli Federico II

M

Marcela F. Pasetti

Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine

F

Francesco Berlanda Scorza

GSK Vaccines Institute for Global Health

C

Carlo Giannelli

GSK Vaccines Institute for Global Health

O

Omar Rossi

GSK Vaccines Institute for Global Health

F

Francesca Micoli

GSK Vaccines Institute for Global Health

C

Claudia Sala

R

Rino Rappuoli